Pharmalot... Pharmalittle... Good Morning

Good morning, everyone, and welcome to another working week. We hope the weekend break was relaxing. Now, though, the rourine of meetings and deadlines has resumed, a task made still more difficult by the soggy climate in the part of the world where the Pharmalot corporate campus is located. Nonetheless, we will all persevere. However, we will, unfortunately, have to break early today to say farewell to a special Pharmalot ancestor who passed away yesterday. But we will return tomorrow. Meanwhile, here is the usual menu of tidbits. Hope your day goes well and be in touch... New Leukemia Drugs Offer Potential For Chemo-Free Treatment (Bloomberg News) FDA Approves $1,000-A-Day Gilead Pill For Hepatitis C (Reuters) FDA Issues Warning Letter To Jubilant For Problems At US Plant (Outsourcing Pharma) Covidien Buys 'PillCam' Maker For $860 Million (Ha'aretz) Some Diabetes Drug Reduce Cancer Risk In Women: Study (Los Angeles Times) Novartis Myeloma Drug Clears Phase III Trial (PM Live) AbbVie Leukemia Drug Performs Well In Early-Stage Trial (Reuters) UK's NICE Backs Sanofi Aubagio Drug For MS (...Read more
Source: Pharmalot - Category: Pharma Commentators Authors: Source Type: blogs